Sovereign fast-track vouchers collapse drug review timelines from months to mere weeks.
The FDA's National Priority Voucher program is bypassing traditional review periods to grant major regulatory clearances in under two months for therapies addressing critical public health needs.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The approval of Rasonque was drastically accelerated under the FDA's CNPV Pilot Program, which compresses typical review timelines down to just weeks.
The FDA's CNPV program successfully fast-tracks drug reviews down to under two months for products aligned with national healthcare priorities.
Casgevy's pediatric expansion was approved in just 53 days from filing under the ultra-fast CNPV pathway.
Revolution Medicines secured approval for its highly anticipated pancreatic cancer therapy far ahead of schedule by leveraging the FDA's rapid review program.